Company Search:
Advanced Search
Sponsored Links
Novavax, Inc. Company Snapshot
Novavax, Inc. operates in the Biological products exc. diagnostic sector. In addition to historical fundamental analyses, the complete report available to purchase compares Novavax with three other companies in this sector in the United States: Teligent Inc (2015 sales of $44.25 million of which 100% was Cosmetic Products), Novocure Ltd ($33.09 million of which 100% was Pharmaceutical), and Sangamo Therapeutics Inc ($39.54 million of which 100% was Research & Colloboration).

Sales Analysis. Novavax reported sales of $36.25 million for the year ending December of 2015. This represents an increase of 18.2% versus 2014, when the company's sales were $30.66 million.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Novavax, Inc.
  Stock Performance Chart for Novavax, Inc.
  Stock Data: Recent Stock Performance:
  Current Price (1/20/2017): 1.35
(Figures in U.S. Dollars)
1 Week -5.6%   13 Weeks -2.9%  
4 Weeks -11.2%   52 Weeks -79.6%  
Novavax, Inc. Key Data:
  Ticker: NVAX Country: United States
  Exchanges: NAS Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Biological Products Exc. Diagnostic
  2015 Sales 36,250,000
(Year Ending Jan 2016).
Employees: 443
  Currency: U.S. Dollars Market Cap: 366,182,055
  Fiscal Yr Ends: December Shares Outstanding: 271,245,967
  Share Type: Common Closely Held Shares: 4,174,930
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.